Zoledronic Acid Injection Zobone 4mg

Zoledronic Acid Injection Zobone 1 is a bisphosphonate, a type of drug used to treat osteoporosis (weak and brittle bones) caused by menopause or long-term steroid usage. Paget’s bone and high calcium levels induced by cancer are also treated with Zobone 4mg Injection 1.

This medicine is used to treat elevated calcium levels in the blood (hypercalcemia), which can occur as a result of cancer. Zoledronic acid is also used in conjunction with cancer chemotherapy to treat bone issues associated with multiple myeloma and other cancers that have progressed to the bones (e.g., breast, lung).

The most prevalent side effect linked with zoledronic acid infusion is fever. Flu-like symptoms such as fever, chills, bone pain, and/or arthralgia, and myalgias have been observed on occasion.

• For patients taking zoledronic acid, the following adverse effects are prevalent (occurring in more than 30% of cases):

• Ostealgia.

• Nausea.

• Fever is usually moderate and brief.

• Fatigue.

• Anemia.

• Vomiting.

• Constipation.

• Symptoms of the flu include a low temperature, malaise, chills, lethargy, and flushing.

Intravenous administration. Zoledronic Acid Injection (5 mg in 100 mL ready-to-infuse solution) is infused slowly and at a steady rate through a vented infusion line. The duration of the infusion must be shorter than 15 minutes.

In women who have gone through menopause (the end of regular menstrual periods), zoledronic acid (Reclast) is used to prevent or treat osteoporosis (a condition in which the bones become thin, fragile, and easily break).

According to a study presented at the American Society for Bone and Mineral Research (ASBMR) 2017 Annual Meeting held September 8-11 in Denver, Colorado, patients treated with zoledronic acid had a higher risk of heart failure and other cardiovascular diseases.

Zoledronic Acid Injection exhibited an acceptable safety profile; no drug-related adverse events were reported. Even in high-risk individuals, ZA treatment enhanced bone health by increasing bone mineral density and decreasing bone turnover.

The best time to take zoledronic acid has yet to be discovered. Doctors should consider discontinuing medication after 3 to 5 years in patients with osteoporosis who are at low risk of fracture. Patients who stop taking their medication should have their fracture risk assessed on a regular basis.

Check this Product Arthritis Aclopride-TA Tablet or you may explore more Arthritis by clicking here

We are an exporter from India and work in excess countries like the UAE , Oman, Qatar, Myanmar, Saudi Arabia, Netherland, Albania, Saint lucia , Jordan , Romania ,South africa , and so on.